Specifically designed by the Society for Immunotherapy of Cancer (SITC), the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CNE-, CPE- and MOC-certified programs, presented by leading, local authorities in tumor immunology and cancer immunotherapy.Highlights of these programs include the following:
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live virtual event, through four quarterly webinars, and indefinitely through a dedicated online SITC CONNECT community forum.SITC has partnered with the American Academy of Emergency Medicine (AAEM), Association of Community Cancer Centers (ACCC) and the Hematology/Oncology Pharmacy Association (HOPA) to provide guidance for emergency physicians in identifying and managing patients who present to the ER with immune-related adverse events, and practical information about the necessary hospital operations for providing immunotherapy and strategies for obtaining reimbursement.
The target audience for ACI program series is patient care providers and others who wish to learn the basic principles of tumor immunology and immunotherapy, and to improve their ability to integrate immunotherapy into state-of-the-art clinical management for their patients. This intended audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, physician assistants, emergency physicians, allied health professionals, other patient care providers, students and patient advocates.
The topics that will be covered during each program in the series are as follows:
Either the content you're seeking doesn't exist or it requires proper authentication before viewing.
The 2020–2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org